08.17.10
Colin W. Stewart has been appointed president, chief executive officer of Amarin Corp. and a member of the company's board of directors, effective August 16, 2010.Mr. Stewart will be responsible for driving the company's strategy to maximize the value of its lead product, AMR101, in Phase III trials for the treatment of high triglycerides. Results from the company’s Phase III MARINE trial are expected in early 2011.
Mr. Stewart has more than 30 years of experience in executive management and commercial positions for pharmaceutical companies, including five years as president and chief executive officer of CollaGenex Pharmaceuticals, Inc. Mr. Stewart also served ten years with the ASTA Medica Group, where he managed several business units in the U.S. and internationally.
Amarin's chairman of the board, Joseph Zakrzewski, commented, "We are very excited by the addition of Colin Stewart to the Amarin team.He brings a wealth of commercial and executive management experience, which complements the already strong technical and financial functions within the Company. Colin is expected to play a key role as we weigh our various alternatives for commercialization of AMR101."
Mr. Stewart has more than 30 years of experience in executive management and commercial positions for pharmaceutical companies, including five years as president and chief executive officer of CollaGenex Pharmaceuticals, Inc. Mr. Stewart also served ten years with the ASTA Medica Group, where he managed several business units in the U.S. and internationally.
Amarin's chairman of the board, Joseph Zakrzewski, commented, "We are very excited by the addition of Colin Stewart to the Amarin team.He brings a wealth of commercial and executive management experience, which complements the already strong technical and financial functions within the Company. Colin is expected to play a key role as we weigh our various alternatives for commercialization of AMR101."